K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Entry into a Material Definitive Agreement

K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

Story continues below

On October 6, 2017, K2M Group Holdings, Inc. (“K2M” or the “Company”) and certain of its subsidiaries entered into an amendment (the “Tenth Amendment”) to the Company’s senior secured credit facilities credit agreement, dated as of October 29, 2012 (as amended from time to time), by and among K2M Holdings, Inc. as the guarantor, K2M, Inc. and K2M UK Limited as the borrower, and Silicon Valley Bank and Comerica Bank as lenders. The Tenth Amendment extends the maturity date of the revolving credit facility from April 26, 2018 to April 26, 2019, among other changes.

The above summary is qualified in its entirety by reference to the full text of the Tenth Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 1.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

10.1

Tenth Amendment dated October 6, 2017 to Credit Agreement dated October 29, 2012, by and among K2M Holdings, Inc., as the guarantor, K2M, Inc. and K2M UK Limited, as borrowers, and Silicon Valley Bank and Comerica Bank as lenders.


K2M GROUP HOLDINGS, INC. Exhibit
EX-10.1 2 exhibit101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1Executed Version    TENTH AMENDMENT TO CREDIT AGREEMENTThis Tenth Amendment to Credit Agreement (this “Amendment”) is entered into as of October 6,…
To view the full exhibit click here

About K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company’s technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.

An ad to help with our costs